Topical alkane vapocoolant spray versus subcutaneous lignocaine injection for reducing the pain of intravenous cannulation: a randomised, controlled, clinical trial
A randomised clinical trial to compare the efficacy of pressurised vapocoolant spray and subcutaneous lignocaine injection in decreasing the pain of intravenous cannulation in the emergency department
Austin Health
220 participants
Oct 1, 2008
Interventional
Conditions
Summary
Our previous research indicates vapocoolant is effective in significantly decreasing the pain of intravenous cannulation. This new study will compare vapocoolant with subcutaneous lignocaine, another common means of reducing the pain of cannulation.
Eligibility
Inclusion Criteria1
- Emergency department patients, aged 18 years or more, requiring intravenous cannulation
Exclusion Criteria8
- Refusal to provide consent
- Inability to provide informed consent (Non-English speaking, altered mental state, significant illness, urgent need for IV cannulation)
- Moderate to severe discomfort or pain
- Diseases of the skin associated with cold intolerance (eg: Raynaud’s)
- Known allergy to spray contents or lignocaine
- Peripheral neuropathy
- Parenteral analgesia in the previous 4 hours
- Use of other local anaesthetics
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Two second spray of pressurised vapocoolant 'Cold Spray' (butane, propane and pentane blend), from 12 cm, to the cannulation site. The alkane blend may vary with the batch and specific proportions of the three alkanes are not available.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12608000414314